{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:52:11Z","timestamp":1792716731989,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K23HL151672-01"],"award-info":[{"award-number":["1K23HL151672-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cardfail.2021.12.017","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T10:00:52Z","timestamp":1643018452000},"page":"453-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"title":["Economic Issues in Heart Failure in the United States"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-8490","authenticated-orcid":false,"given":"Paul A.","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9932","authenticated-orcid":false,"given":"Yekaterina","family":"Opsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy K.","family":"Sweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider J.","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Hsich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Bennett","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Sabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2021.12.017_bib0001","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0002","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0003","doi-asserted-by":"crossref","first-page":"E365","DOI":"10.9778\/cmajo.20150130","article-title":"The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis","volume":"4","author":"Tran","year":"2016","journal-title":"CMAJ Open"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016782","article-title":"Trends of clinical outcomes and health care resource use in heart failure in the United States","volume":"9","author":"Khan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jchf.2016.01.003","article-title":"Patient and facility variation in costs of VA heart failure patients","volume":"4","author":"Yoon","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0007","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1377\/hlthaff.2018.05178","article-title":"Decreases in readmissions credited to Medicare's program to reduce hospital readmissions have been overstated","volume":"38","author":"Ody","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2019.07.012","article-title":"The Hospital Readmissions Reduction Program: nationwide perspectives and recommendations: A JACC: Heart Failure Position Paper","volume":"8","author":"Psotka","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamacardio.2017.4265","article-title":"Association of the Hospital Readmissions Reduction Program implementation with readmission and mortality outcomes in heart failure","volume":"3","author":"Gupta","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0011","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/jama.2018.19232","article-title":"Association of the Hospital Readmissions Reduction Program with mortality among Medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and pneumonia","volume":"320","author":"Wadhera","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jacc.2019.04.060","article-title":"Evaluation of 30-day hospital readmission and mortality rates using regression-discontinuity framework","volume":"74","author":"Khera","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0013","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M19-1980","article-title":"Cost-effectiveness of transitional care services after hospitalization with heart failure","volume":"172","author":"Blum","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0014","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jama.2019.0710","article-title":"Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the PACT-HF randomized clinical trial","volume":"321","author":"Van Spall","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCULATIONAHA.117.027551","article-title":"Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC Study Community Surveillance","volume":"138","author":"Chang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0017","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1002\/ehf2.13043","article-title":"Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak","volume":"7","author":"Severino","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0018","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jchf.2020.05.014","article-title":"Clinical characteristics and trends in heart failure hospitalizations: an Australian experience during the COVID-19 lockdown","volume":"8","author":"Toner","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0019","first-page":"1680","article-title":"Reduced rate of hospital presentations for heart failure during the COVID-19 pandemic in Toronto, Canada","volume":"36","author":"Frankfurter","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cardfail.2020.05.005","article-title":"Reductions in heart failure hospitalizations during the COVID-19 pandemic","volume":"26","author":"Hall","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0021","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","article-title":"Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic","volume":"76","author":"Bhatt","year":"2020","journal-title":"J AM Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0022","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cardfail.2020.04.008","article-title":"Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America","volume":"26","author":"Gorodeski","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ehf2.13061","article-title":"Insights into heart failure hospitalizations, management, and services during and beyond COVID-19","volume":"8","author":"Charman","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0024","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"129","author":"Anderson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0025","unstructured":"The World Bank. GDP per capita, United States. Available at: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?end=2019&locations=US&start=2019&view=chart. Accessed December 13, 2020."},{"key":"10.1016\/j.cardfail.2021.12.017_bib0026","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0027","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0028","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0029","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0735-1097(95)00284-1","article-title":"Cost-effectiveness of captopril therapy after myocardial infarction","volume":"26","author":"Tsevat","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0030","first-page":"1","article-title":"Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness","author":"Shekelle","year":"2003","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0031","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/M16-0057","article-title":"Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction","volume":"165","author":"Sandhu","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0032","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1994.00420100129016","article-title":"Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure","volume":"154","author":"Paul","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003221","article-title":"Cost-effectiveness of ivabradine for heart failure in the United States","volume":"5","author":"Kansal","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0034","doi-asserted-by":"crossref","first-page":"74S","DOI":"10.1016\/S0002-9343(98)00387-8","article-title":"Economic impact of beta blockade in heart failure","volume":"110","author":"Gregory","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1015371616135","article-title":"Economic evaluation of the Randomized Aldactone Evaluation Study (RALES): treatment of patients with severe heart failure","volume":"16","author":"Glick","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0036","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0037","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0002-9149(98)01066-2","article-title":"Cost effectiveness of carvedilol for heart failure","volume":"83","author":"Delea","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0038","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2012.12.022","article-title":"Incremental cost-effectiveness of guideline-directed medical therapies for heart failure","volume":"61","author":"Banka","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0039","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1161\/CIRCULATIONAHA.105.563882","article-title":"Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure","volume":"112","author":"Angus","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0040","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0041","doi-asserted-by":"crossref","first-page":"A15981","DOI":"10.1161\/circ.142.suppl_3.15981","article-title":"Cost-effectiveness of dapagliflozin in heart failure with reduced ejection fraction","volume":"142","author":"Isaza","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0042","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2017.01.003","article-title":"Trends in health care expenditure among USadults with heart failure: The Medical Expenditure Panel Survey 2002-2011","volume":"186","author":"Echouffo-Tcheugui","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0043","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0044","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction","volume":"5","author":"Gaziano","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0045","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0046","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0047","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0048","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40273-018-0709-3","article-title":"Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia","volume":"36","author":"Bounthavong","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0050","series-title":"CardioMEMS\u2122 HF System (St. Jude Medical, Inc.) and sacubitril\/valsartan (Entresto\u2122, Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks","author":"Ollendorf","year":"2015"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0051","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamainternmed.2015.7661","article-title":"Sacubitril-valsartan for the treatment of heart failure: effectiveness and value","volume":"176","author":"Ollendorf","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0052","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011783","article-title":"Increasing the adoption and diffusion of a novel pharmacological therapy that is both mortality reducing and cost-effective","volume":"8","author":"Bergethon","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0053","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2019.21428","article-title":"Refocusing medication prior authorization on its intended purpose","volume":"323","author":"Resneck","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0054","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.healthpol.2017.02.008","article-title":"Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure","volume":"121","author":"Gourzoulidis","year":"2017","journal-title":"Health Policy"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.298.1.61","article-title":"Prescription drug cost sharing: associations with medication and medical utilization and spending and health","volume":"298","author":"Goldman","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0056","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jama.2018.19791","article-title":"Effect of Medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial","volume":"321","author":"Wang","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0057","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","article-title":"Full coverage for preventive medications after myocardial infarction","volume":"365","author":"Choudhry","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0058","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of sacubitril\/valsartan for the management of patients with heart failure","volume":"11","author":"Sangaralingham","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0059","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.120.053291","article-title":"The affordability of guideline-directed medical therapy: cost sharing is a critical barrier to therapy adoption","volume":"143","author":"Sandhu","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0060","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0061","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0062","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10198-014-0637-x","article-title":"Economic evaluations of implantable cardioverter defibrillators: a systematic review","volume":"16","author":"Garcia-Perez","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0063","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMsa051989","article-title":"Cost-effectiveness of implantable cardioverter-defibrillators","volume":"353","author":"Sanders","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0064","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jval.2011.05.030","article-title":"[Cost effectiveness of implantable cardioverter-defibrillators for patients who are at risk for sudden death in Argentina]","volume":"14","author":"Alcaraz","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2010.04.021","article-title":"Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age","volume":"160","author":"Sanders","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0066","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10198-015-0752-3","article-title":"A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure","volume":"17","author":"Tomini","year":"2016","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0067","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/eurheartj\/ehi662","article-title":"Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial","volume":"26","author":"Calvert","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0068","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0069","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0070","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0071","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M14-1804","article-title":"Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure","volume":"163","author":"Woo","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0072","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40258-018-0439-x","article-title":"A systematic review of cost-effectiveness analyses of left ventricular assist devices: issues and challenges","volume":"17","author":"Schmier","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0073","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0074","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.healun.2014.04.010","article-title":"Sixth INTERMACS annual report: a 10,000-patient database","volume":"33","author":"Kirklin","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0075","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"Slaughter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0076","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jacc.2009.03.055","article-title":"Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device","volume":"54","author":"Pagani","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0077","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"a fully magnetically levitated left ventricular assist device - final report","volume":"380","author":"Mehra","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0078","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2013.12.015","article-title":"Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program","volume":"171","author":"Clarke","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0079","first-page":"1","volume":"17","author":"Sutcliffe","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0080","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.healun.2006.09.011","article-title":"Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK)","volume":"25","author":"Sharples","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0081","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.healun.2011.10.017","article-title":"Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation","volume":"31","author":"Moreno","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0082","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCHEARTFAILURE.113.000807","article-title":"Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure","volume":"7","author":"Long","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0083","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchf.2016.09.008","article-title":"Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure","volume":"5","author":"Baras Shreibati","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0084","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/MAT.0000000000001209","article-title":"Cost-effectiveness of thoracotomy approach for the implantation of a centrifugal left ventricular assist device","volume":"66","author":"Mahr","year":"2020","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0085","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MAT.0000000000001211","article-title":"Cost-effectiveness of a small intrapericardial centrifugal left ventricular assist device","volume":"66","author":"Silvestry","year":"2020","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0086","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCHEARTFAILURE.113.000807","article-title":"Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure","volume":"7","author":"Long","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0087","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral- valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0088","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.119.043275","article-title":"Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT Trial","volume":"140","author":"Baron","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0089","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0090","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0091","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archinte.166.10.1081","article-title":"Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea","volume":"166","author":"Mueller","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0092","article-title":"B-type natriuretic peptide-guided treatment for heart failure","volume":"12","author":"McLellan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0093","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2018.08.2184","article-title":"Economic and quality-of-life outcomes of natriuretic peptide-guided therapy for heart failure","volume":"72","author":"Mark","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0094","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2003.10.043","article-title":"Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction","volume":"43","author":"Heidenreich","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0095","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","article-title":"Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction","volume":"70","author":"Givertz","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0096","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jchf.2015.12.015","article-title":"Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure","volume":"4","author":"Sandhu","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0097","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/clc.22696","article-title":"Cost-effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system","volume":"40","author":"Schmier","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0098","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ejhf.642","article-title":"Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial","volume":"19","author":"Martinson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0099","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2021.12.017_bib0100","first-page":"1","article-title":"Cost and value in contemporary heart failure clinical guidance documents","volume":"10","author":"Ostrominski","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642200001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642200001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:47:16Z","timestamp":1761029236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191642200001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S107191642200001X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2021.12.017","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Issues in Heart Failure in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2021.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}